DOC
2,5-Dimethoxy-4-chloroamphetamine
DOC is a psychedelic amphetamine of the DOx family, first synthesized in 1972 at the University of Alberta and later documented by Alexander Shulgin in PiHKAL (1991). It is characterized by its long duration, strong visual effects, and prominent stimulant properties. DOC is highly dose-sensitive and often sold on blotter paper.1 Its intense body load and potency make it particularly challenging for those inexperienced with psychedelics.
Contents
Dosage & Duration
Dosage
Threshold0.5-1 mg
Light1-1.5 mg
Moderate1.5-2 mg
Strong2-4 mg
Heavy4+ mg
DOC is highly dose-sensitive and is often distributed on blotting paper. Its effects can last 12-24 hours, so a full day should be set aside; dosing early in the day is advisable.
Duration
Onset1-2 hours
Come Up2-3 hours
Peak6-12 hours
Offset2-8 hours
After Effects6-24 hours
Total12-24 hours
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of DOC can be broken down into several components which progressively intensify proportional to dosage. These are described below and generally include:
Cognitive
The cognitive effects of DOC are described by many as extreme mental stimulation combined with a powerful enhancement of a person's current mental state. The total sum of these cognitive components regardless of the setting generally includes:
Visual
Distortions
DOC presents a full and complete array of possible visual distortions which generally includes:
Enhancements
DOC presents a full and complete array of possible visual enhancements which generally includes:
Geometry
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of 4-AcO-DMT or ayahuasca than that of LSD, 2C-B or 2C-I. It can be comprehensively described through its variations as intricate in complexity, abstract in form, organic in feel, structured in organization, brightly lit, multicoloured in scheme, glossy in shading, sharp in edges, large in size, fast in speed, smooth in motion, equally rounded and angular in its corners, non-immersive in depth and consistent in intensity. At higher dosages this geometry is significantly more likely to result in states of level 8B visual geometry over level 8A.
Hallucinatory States
DOC and other substituted amphetamines produce a full range of high level hallucinatory states in a fashion that is more consistent and reproducible than that of many other commonly used psychedelics. This holds particularly true in comparison to other substances within the phenethylamine family. These effects include:
Auditory
The auditory effects of DOC are common in their occurrence and exhibit a full range of effects which commonly includes:
Reagent Testing
Loading reagent data
Expected colorimetric results are being prepared.
Pharmacology
Pharmacodynamics
DOC acts as a selective partial agonist at serotonin 5-HT2A, 5-HT2B, and 5-HT2C receptors, with its psychedelic effects believed to be primarily mediated through activity at the 5-HT2A receptor,2 though the precise mechanisms by which this interaction produces the psychedelic experience remain unclear. Its selectivity for the 5-HT2 receptor subfamily has made it a commonly used tool in pharmacological research on these receptors. DOC also displays very weak agonist activity at trace amine-associated receptor 1 (TAAR1).
Pharmacokinetics
Absorption & half-lifenot documented yetMetabolitesnone documented yet
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Full Tolerance
Tolerance to the effects of DOC develops almost immediately after ingestion. Unlike many substances, tolerance does not build significantly without repeated use over a short period of time.
Baseline Reset
Full baseline tolerance is typically restored after approximately 7 days of abstinence from DOC.
Half Tolerance
Approximately 3 days after ingestion, tolerance is reduced to roughly half of its peak level.
Cross Tolerance
Serotonergic psychedelics (LSD, psilocybin, mescaline, DMT), Other phenethylamine psychedelics (2C-x series, DOx series), 5-HT2A agonists
Harm Potential
Addiction & Dependence
Psychological
Extremely LowDOC is not habit-forming and the desire to use it typically decreases with use, exhibiting a self-regulating quality. However, rodent studies have demonstrated reinforcing effects including conditioned place preference and self-administration similarly to methamphetamine.3
Physical
Extremely LowDOC is not physically addictive and does not appear to produce physical dependence or withdrawal symptoms.2
Toxicity
Cardiovascular
At overdose-level doses, DOC can cause significantly elevated heart rate, blood pressure, and severe vasoconstriction; individuals with pre-existing hypertension may be particularly at risk as the amphetamine-like pharmacology causes sharp increases in systolic blood pressure.4
Pulmonary
Pulmonary edema was noted in a fatal DOC overdose case, though data is limited to individual case reports rather than systematic study.2
Psychosis Risk
Psychosis, delusions, and bizarre or violent behavior may occur at high doses or in overdose scenarios. The substance's high dose sensitivity and unusually long duration increase the risk of adverse psychological reactions, particularly in those without extensive hallucinogen experience.4
Seizure Risk
Seizures have been associated with DOC use in medical literature and may occur at high doses or in overdose situations.4
History & Culture
Discovery and Synthesis
DOC was originally synthesized by Ronald Coutts and Jerry Malicky at the University of Alberta in Canada.6 Their work describing the compound was published in the scientific literature in 1973 as part of research into analogues of DOM and related substituted
Legality
International
DOC is listed in Schedule I of the Convention on Psychotropic Substances of 1971. It is not listed under the 1961 Single Convention on Narcotic Drugs. It is not listed under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances.
By Country
United StatesIllegal (analog/blanket ban)Schedule I
Not federally scheduled, but may be prosecuted as an analogue of DOM or DOB under the Federal Analogue Act when sold for human consumption or possessed with intent to ingest. Specifically listed as Schedule I in Florida state law.
By state
Across the 50 states, D.C., and the permanent territories, most jurisdictions treat DOC consistently with federal control; listed entries record independently verified differences in state classification or coverage.
AlabamaIllegalSchedule I controlled substance
ArizonaIllegalDangerous drug
FloridaIllegalSchedule I controlled substance
IdahoIllegalSchedule I controlled substance
IowaNot schedulednot_listed_in_state_schedules
MinnesotaIllegalSchedule I hallucinogenic substance
NebraskaIllegalSchedule I hallucinogenic substance
New MexicoIllegalSchedule I
North CarolinaIllegalSchedule I controlled substance
OklahomaIllegalSchedule I
South DakotaIllegalSchedule I controlled substance
VermontIllegalregulated-stimulant-drug
VirginiaIllegalschedule-i-hallucinogen
AustriaIllegalAnhang V
DOC is listed in Anhang V.1 of Austria's Suchtgiftverordnung and is treated as a Suchtgift under the Suchtmittelgesetz. Unauthorized acquisition, possession, production, transport, import, export, offering, supply, or procurement of DOC is punishable under section 27 of the Suchtmittelgesetz. The Suchtgift-Grenzmengenverordnung sets a 1.0-gram large-quantity threshold for DOC.
BrazilIllegalLista F2
Listed on Portaria SVS/MS nº 344. Possession, production, and sale are prohibited.18
ChinaCategory I psychotropic substanceCitation needed
Controlled since October 2015. Illegal to sell, buy, import, export, or manufacture without authorization.
Czech RepublicIllegalSeznam č. 4
Government Regulation No. 463/2013 Coll., Annex 4 (as amended by Government Regulation No. 243/2015 Coll.)232425
DOC has been listed in Seznam č. 4 psychotropních látek under Government Regulation No. 463/2013 Coll. since 1 October 2015, when Government Regulation No. 243/2015 Coll. replaced Annex 4. Under section 3(2) of Act No. 167/1998 Coll., substances in Annex 4 and preparations containing them may be used only for limited research, scientific and very limited therapeutic purposes specified in a handling permit. Production, storage, supply, use, purchase and sale are regulated forms of handling; a transfer or sale may be made only to a person authorized to handle the substance.
FinlandIllegalLiite I
Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista 543/200826
Possession, production, and sale are prohibited under national drug legislation.
IndiaIllegalPsychotropic substance
Narcotic Drugs and Psychotropic Substances Act, 1985, section 2(xxiii), section 8(c), and Schedule entry 110ZO (inserted by S.O. 1275(E), 23 March 2021)28
DOC is directly listed as "4-Chloro-2,5-dimethoxyamfetamine" at entry 110ZO in the Schedule of psychotropic substances to India's Narcotic Drugs and Psychotropic Substances Act, 1985. The official India Code consolidation attributes that entry to Notification S.O. 1275(E), dated 23 March 2021. Section 2(xxiii) defines a substance in that Schedule as a psychotropic substance, and section 8(c) prohibits the specified operations involving it except for medical or scientific purposes as provided by the Act, rules, or orders and any applicable licence, permit, or authorisation. The listing names DOC itself, rather than only an analogue, constituent, or specified product.
IrelandIllegal (analog/blanket ban)Schedule 1 structural derivative
Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/20223132333435
DOC is not named individually; its 2,5-dimethoxy and 4-chloro ring substitutions place it within the Schedule 1 definition for a substance structurally derived from alpha-methylphenethylamine with alkoxy or halo ring substituents. The 2022 Designation Order applies section 13(1) of the Misuse of Drugs Act 1977 to that Schedule 1 class; the Act prohibits possession of a controlled drug, and the Regulations prohibit production, supply, importation, and exportation subject to their specified authorities and exceptions. The current Schedule 1 derives from the 2022 substitution, and the later 2025 amendments affected paragraph 1(a), not paragraph 1(l).
ItalyDecriminalizedTabella I
Decreto del Presidente della Repubblica 9 ottobre 1990, n. 30936
DOC is entered in Tabella I of Italy's consolidated drug law. Unauthorised production and supply are criminal offences, while personal-use conduct is addressed through the decree's administrative-sanction regime.
LatviaIllegalList I
Regulations Regarding Classification of Narcotic and Psychotropic Substances and Medicinal Products39
Classified as a Schedule I controlled substance under Latvian law.
New ZealandIllegalClass C
Misuse of Drugs Act 197541
Controlled as an amphetamine analogue under Schedule III (Class C) of New Zealand's controlled substances legislation.
PolandIllegalGrupa I-P
Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 143444546
DOC is listed as 2,5-dimetoksy-4-chloroamfetamina in Group I-P of Annex 1 to the Health Minister's regulation on psychotropic substances, narcotic drugs, and new psychoactive substances. Group I-P psychotropic substances may be used only for research. Possession contrary to the Act is punishable by imprisonment for up to three years, and unlawful manufacture or supply is subject to separate criminal penalties under the Act on Counteracting Drug Addiction.
SpainIllegalLista I
Real Decreto 2829/1977, de 6 de octubre48
DOC is included in Lista I of Spain's psychotropic-substances schedules. Lista I substances are subject to the decree's control and prohibition regime.
SwitzerlandIllegalVerzeichnis d
DOC is listed in Verzeichnis d of the Betäubungsmittelverzeichnisverordnung. Verzeichnis d is Switzerland's category of prohibited controlled substances. Unauthorised manufacture, sale, possession, storage, and acquisition of narcotics are punishable under the Narcotics Act; federal exceptions are available for specified research, medicine-development, and limited medical uses.
TurkeyIllegal (analog/blanket ban)AMFETAMİN (FENİLETİLAMİN) TÜREVLERİ
26/1/2015 tarihli ve 2015/7238 sayılı Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması Hakkında Karar59
Classified as a controlled drug. Illegal to possess, produce, supply, or import.
AustraliaIllegalSchedule 9
As of 1 June 2026, the Poisons Standard classifies DOC as a Schedule 9 prohibited substance through its entry for alkoxyamfetamines and substituted alkoxyamfetamines. Schedule 9 restricts manufacture, possession, supply and use to approved medical, scientific, analytical, teaching or training purposes under Commonwealth and State or Territory health-authority arrangements. At the Commonwealth border, the Customs (Prohibited Imports) Regulations 1956 specifically list DOC as a Schedule 4 drug, and importation requires both a licence and permission.
BelgiumIllegal (analog/blanket ban)Annex IVa
Royal Decree of 6 September 2017 regulating narcotic drugs and psychotropic substances, Annex IVa, Figure 1 (1-phenylpropan-2-amine derivatives), and Article 61415
DOC is not named in the decree's schedules, but its 2,5-dimethoxy-4-chloroamphetamine structure is a substituted 1-phenylpropan-2-amine within the generic class in Annex IVa. The current consolidated decree subjects Annex IV substances to the activity-authorisation regime; that authorisation is personal and limited to scientific or medical purposes.
CanadaIllegalSchedule I
Controlled Drugs and Substances Act, Schedule I19
Controlled under the Controlled Drugs and Substances Act.20 Additionally covered by the 2016 regulation controlling phenethylamines with a 2,5-dimethoxyphenylethamine core structure. Illegal to sell, buy, or possess without valid legal exemption.
ColombiaRestrictedLista Nacional
Resolution No. 000116 of 2026 took effect on 27 January 2026 and replaced the technical annexes adopted by Resolution No. 315 of 2020. Its revised Technical Annex 1 lists DOC (2,5-Dimetoxi-4-cloroamfetamina) at No. 194 in Lista Nacional, the national list of substances subject to special control and fiscalization. This is a national control designation, not a Green List I psychotropic designation.
DenmarkSchedule ICitation needed
Added to the list of Schedule I controlled substances as of April 8, 2007, alongside 2C-E, 2C-P, and DOI.
GermanyIllegalAnlage I
Betäubungsmittelgesetz, Anlage I27
Listed in Anlage I of the Betäubungsmittelgesetz (Narcotics Act) since February 1, 1997.27 Manufacturing, possession, importation, exportation, purchase, sale, procurement, and dispensing are all prohibited without a license.
IndonesiaIllegalNarkotika Golongan I
DOC is expressly listed as 1-(4-Kloro-2,5-dimetoksifenil)propan-2-amina in the Group I narcotics schedule annexed to Peraturan Menteri Kesehatan Nomor 15 Tahun 2025. The regulation defines Group I narcotics as substances usable only for scientific development and not for therapy. It was promulgated on 28 November 2025, entered into force that day, and repealed Peraturan Menteri Kesehatan Nomor 7 Tahun 2025; the Ministry of Health's official legal-information database records it as in force.
IsraelControlledCitation needed
Possession, production, and sale are prohibited under national drug legislation.
JapanIllegal麻薬
DOC (1-(4-chloro-2,5-dimethoxyphenyl)propan-2-amine) and its salts are designated as narcotics (麻薬) by Japan's Cabinet Order Designating Narcotics, Narcotic Raw Material Plants, Psychotropic Substances and Narcotic and Psychotropic Substance Raw Materials. The Narcotics and Psychotropics Control Act restricts manufacture, transfer, and possession of narcotics to licensed or specifically authorised persons; unlicensed possession, manufacture, and sale or transfer are prohibited.
NetherlandsIllegalLijst I
Opiumwet, Lijst I40
DOC (4-chloor-2,5-dimethoxyamfetamine) is expressly included in Lijst I of the Opiumwet. Article 2 prohibits importing, exporting, preparing, processing, selling, supplying, transporting, possessing, and manufacturing List I substances, subject to the Act's authorized exemptions and dispensations.
NorwayIllegalNarkotikalisten
Forskrift om narkotika42
DOC is included in Norway's national narcotics list as 4-chloro-2,5-dimethoxyamphetamine. The regulation treats listed substances as narcotics under the Norwegian control regime.
SingaporeIllegalClass A
Misuse of Drugs Act 197347
DOC is a Class A controlled drug in Part I of the First Schedule to Singapore's Misuse of Drugs Act. The Act criminalises unauthorised possession, trafficking, manufacture, import, export, and consumption of controlled drugs.
SwedenIllegalFörteckning I (P I)
DOC is listed as 4-klor-2,5-dimetoxiamfetamin in Förteckning I of the Swedish Medical Products Agency's current consolidated narcotics schedule. The schedule states that Förteckning I covers substances that normally have no medical use; the Government's current Ordinance (1992:1554) identifies DOC as a substance deemed narcotic under the Narcotic Drugs Penal Law, which criminalises unauthorised possession, use, transfer, manufacture, and other handling of narcotics.
ThailandIllegalCategory I
Notification of the Ministry of Public Health Re: Specifying Names of Narcotics in Category 1, B.E. 2565 (2022)565758
DOC is expressly listed as 4-chloro-2,5-dimethoxyamphetamine in Category I of the Ministry of Public Health notification made under Thailand's Narcotics Code. The notification was published on 25 October 2022 and took effect 30 days later. Unauthorized production, import, export, sale, or possession of a Category I narcotic is punishable by up to 15 years' imprisonment and a fine of up to 1,500,000 baht.
References
Source Pages
Citations
- Shulgin, Alexander, & Shulgin, Ann. (1991). #64. DOC. PiHKAL: A Chemical Love Story. https://erowid.org/library/books_online/pihkal/pihkal064.shtml123
- World Health Organization Expert Committee on Drug Dependence. (2019). Critical Review Report: DOC (4-Chloro-2,5-dimethoxyamfetamine). World Health Organization. https://researchonline.ljmu.ac.uk/id/eprint/11444/1/ECDD42_DOC.pdf1234
- Cha, H. J., & et al.. (2018). Rewarding and reinforcing effects of 4-chloro-2,5-dimethoxyamphetamine and AH-7921 in rodents. Neuroscience Letters. https://doi.org/10.1016/j.neulet.2018.04.0091
- (2015). Hallucinogens Causing Seizures? A Case Report of the Synthetic Amphetamine 2,5-Dimethoxy-4-Chloroamphetamine. https://doi.org/10.1177/1941874414528939123
- (2014). A Fatal Intoxication of 2,5-Dimethoxy-4-Chloroamphetamine: A Case Report. https://doi.org/10.1093/jat/bku0871
- (1973). The Synthesis of Some Analogs of the Hallucinogen 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM). https://doi.org/10.1139/v73-21012
- Dawson, B. A., & Neville, G. A.. (1989). Identification of Two New "Designer" Amphetamines by NMR Techniques. Canadian Society of Forensic Science Journal, 22(2), 195-202. https://doi.org/10.1080/00085030.1989.107574331
- (n.d.). Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au. https://www.legislation.gov.au/F2026L00633/asmade/2026-05-28/text/original/epub/OEBPS/document_1/document_1.html1
- (n.d.). Therapeutic Goods (Poisons Standard—June 2026) Instrument 2026. legislation.gov.au. https://www.legislation.gov.au/F1996B03651/2026-03-26/2026-03-26/text/original/epub/OEBPS/document_1/document_1.html1
- (n.d.). Suchtgiftverordnung, Anhang V. ris.bka.gv.at. https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053&Anlage=51
- (n.d.). Suchtgiftverordnung, Anhang V. ris.bka.gv.at. https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011053&Paragraf=11
- (n.d.). Suchtgiftverordnung, Anhang V. ris.bka.gv.at. https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011040&Paragraf=271
- (n.d.). Suchtgiftverordnung, Anhang V. ris.bka.gv.at. https://www.ris.bka.gv.at/NormDokument.wxe?Abfrage=Bundesnormen&Gesetzesnummer=10011056&Anlage=11
- (n.d.). Royal Decree of 6 September 2017 regulating narcotic drugs and psychotropic substances, Annex IVa, Figure 1 (1-phenylpropan-2-amine derivatives), and Article 6. ejustice.just.fgov.be. https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- (n.d.). Royal Decree of 6 September 2017 regulating narcotic drugs and psychotropic substances, Annex IVa, Figure 1 (1-phenylpropan-2-amine derivatives), and Article 6. ejustice.just.fgov.be. https://www.ejustice.just.fgov.be/mopdf/2017/09/26_1.pdf#page=2191
- (n.d.). Portaria SVS/MS nº 344/1998, Lista F2. bvsms.saude.gov.br. https://bvsms.saude.gov.br/bvs/saudelegis/anvisa/2007/rdc0044_02_07_2007.html1
- (n.d.). Portaria SVS/MS nº 344/1998, Lista F2. bvsms.saude.gov.br. https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html1
- (December 2, 2016). RESOLUÇÃO DA DIRETORIA COLEGIADA - RDC N° 130, DE 2 DE DEZEMBRO DE 2016. Agência Nacional de Vigilância Sanitária (ANVISA). https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&link=S&tipo=RDC&numeroAto=00000130&seqAto=000&valorAno=2016&orgao=RDC/DC/ANVISA/MS&cod_modulo=310&cod_menu=94281
- (n.d.). Controlled Drugs and Substances Act, Schedule I. laws-lois.justice.gc.ca. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-17.html1
- (n.d.). Controlled Drugs and Substances Act (S.C. 1996, c. 19) — Schedule I. Government of Canada. https://laws-lois.justice.gc.ca/eng/acts/C-38.8/page-9.html1
- (n.d.). Government Regulation No. 463/2013 Coll., Annex 4 (as amended by Government Regulation No. 243/2015 Coll.). e-sbirka.cz. https://www.e-sbirka.cz/sb/2015/2431
- (n.d.). Government Regulation No. 463/2013 Coll., Annex 4 (as amended by Government Regulation No. 243/2015 Coll.). e-sbirka.cz. https://www.e-sbirka.cz/sb/2013/4631
- (n.d.). Government Regulation No. 463/2013 Coll., Annex 4 (as amended by Government Regulation No. 243/2015 Coll.). e-sbirka.cz. https://www.e-sbirka.cz/sb/1998/1671
- (n.d.). Valtioneuvoston asetus huumausaineina pidettävistä aineista, valmisteista ja kasveista 543/2008. finlex.fi. https://finlex.fi/fi/lainsaadanto/2008/5431
- (2019). Gesetz über den Verkehr mit Betäubungsmitteln: Anlage I. https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html12
- (n.d.). Narcotic Drugs and Psychotropic Substances Act, 1985, section 2(xxiii), section 8(c), and Schedule entry 110ZO (inserted by S.O. 1275(E), 23 March 2021). indiacode.nic.in. https://www.indiacode.nic.in/bitstream/123456789/1791/5/a1985-61.pdf1
- (n.d.). Peraturan Menteri Kesehatan Nomor 15 Tahun 2025 tentang Perubahan Penggolongan Narkotika. jdih.kemkes.go.id. https://jdih.kemkes.go.id/storage/documents/pdfs/2025permenkes015.pdf1
- (n.d.). Peraturan Menteri Kesehatan Nomor 15 Tahun 2025 tentang Perubahan Penggolongan Narkotika. jdih.kemkes.go.id. https://jdih.kemkes.go.id/documents/peraturan-menteri-kesehatan-nomor-15-tahun-20251
- (n.d.). Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/2022. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/1977/act/12/section/3/enacted/en/html1
- (n.d.). Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/2022. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2017/si/173/made/en/print1
- (n.d.). Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/2022. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2022/si/210/made/en/print1
- (n.d.). Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/2022. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2022/si/211/made/en/print1
- (n.d.). Misuse of Drugs Act 1977, section 3; Misuse of Drugs Act 1977 (Controlled Drugs) (Designation) Order 2022 (S.I. No. 211/2022), Schedule 1, paragraph 1(l); Misuse of Drugs Regulations 2017, regulation 5 and Schedule 1 as substituted by S.I. No. 210/2022. irishstatutebook.ie. https://www.irishstatutebook.ie/eli/2025/si/406/made/en/print1
- (n.d.). Decreto del Presidente della Repubblica 9 ottobre 1990, n. 309. normattiva.it. https://www.normattiva.it/atto/caricaDettaglioAtto?atto.codiceRedazionale=090G0363&atto.dataPubblicazioneGazzetta=1990-10-311
- (n.d.). 麻薬、麻薬原料植物、向精神薬、麻薬向精神薬原料等を指定する政令. elaws.e-gov.go.jp. https://elaws.e-gov.go.jp/api/1/lawdata/402CO00000002381
- (n.d.). 麻薬、麻薬原料植物、向精神薬、麻薬向精神薬原料等を指定する政令. elaws.e-gov.go.jp. https://elaws.e-gov.go.jp/api/1/lawdata/328AC00000000141
- (n.d.). Regulations Regarding Classification of Narcotic and Psychotropic Substances and Medicinal Products. likumi.lv. https://likumi.lv/ta/en/en/id/121086-regulations-regarding-classification-of-narcotic-and-psychotropic-substances-and-medicinal-products-and-illicit-handling-of-narcotic-and-psychotropic-substances1
- (n.d.). Opiumwet, Lijst I. wetten.overheid.nl. https://wetten.overheid.nl/BWBR0001941/2026-07-091
- (n.d.). Misuse of Drugs Act 1975. legislation.govt.nz. https://www.legislation.govt.nz/act/public/1975/0116/latest/DLM436770.html1
- (n.d.). Forskrift om narkotika. lovdata.no. https://lovdata.no/dokument/SF/forskrift/2013-02-14-1991
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 1. api.sejm.gov.pl. https://api.sejm.gov.pl/eli/acts/DU/2024/1139/text.html1
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 1. api.sejm.gov.pl. https://api.sejm.gov.pl/eli/acts/DU/2025/598/text.pdf1
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 1. api.sejm.gov.pl. https://api.sejm.gov.pl/eli/acts/DU/2026/934/text.pdf1
- (n.d.). Rozporządzenie Ministra Zdrowia z dnia 17 sierpnia 2018 r. w sprawie wykazu substancji psychotropowych, środków odurzających oraz nowych substancji psychoaktywnych, załącznik nr 1. api.sejm.gov.pl. https://api.sejm.gov.pl/eli/acts/DU/2023/1939/text.html1
- (n.d.). Misuse of Drugs Act 1973. sso.agc.gov.sg. https://sso.agc.gov.sg/Act/MDA1973?ProvIds=Sc1-1
- (n.d.). Real Decreto 2829/1977, de 6 de octubre. boe.es. https://www.boe.es/buscar/act.php?id=BOE-A-1977-271601
- (n.d.). Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. lakemedelsverket.se. https://www.lakemedelsverket.se/globalassets/dokument/lagar-och-regler/lvfs/lvfs-2011-10-konsoliderad.pdf1
- (n.d.). Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. riksdagen.se. https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/forordning-19921554-om-kontroll-av-narkotika_sfs-1992-1554/1
- (n.d.). Läkemedelsverkets föreskrifter (LVFS 2011:10) om förteckningar över narkotika. riksdagen.se. https://www.riksdagen.se/sv/dokument-och-lagar/dokument/svensk-forfattningssamling/narkotikastrafflag-196864_sfs-1968-64/1
- (n.d.). Betäubungsmittelverzeichnisverordnung, Verzeichnis d. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2011/363/de1
- (n.d.). Betäubungsmittelverzeichnisverordnung, Verzeichnis d. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/2011/362/de1
- (n.d.). Betäubungsmittelverzeichnisverordnung, Verzeichnis d. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/cc/1952/241_241_245/de1
- (n.d.). Betäubungsmittelverzeichnisverordnung, Verzeichnis d. fedlex.admin.ch. https://www.fedlex.admin.ch/eli/oc/2026/117/de1
- (n.d.). Notification of the Ministry of Public Health Re: Specifying Names of Narcotics in Category 1, B.E. 2565 (2022). narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/law-type/nc-3441
- (n.d.). Notification of the Ministry of Public Health Re: Specifying Names of Narcotics in Category 1, B.E. 2565 (2022). narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/media.php?id=509258327683899392&name=NC_344_%E0%B8%9B%E0%B8%A3%E0%B8%B0%E0%B8%81%E0%B8%B2%E0%B8%A8%E0%B8%81%E0%B8%A3%E0%B8%B0%E0%B8%97%E0%B8%A3%E0%B8%A7%E0%B8%87_%E0%B8%9E.%E0%B8%A8._2565_%E0%B8%A3%E0%B8%B0%E0%B8%9A%E0%B8%B8%E0%B8%8A%E0%B8%B7%E0%B9%88%E0%B8%AD_%E0%B8%A2%E0%B8%AA.1.PDF1
- (n.d.). Notification of the Ministry of Public Health Re: Specifying Names of Narcotics in Category 1, B.E. 2565 (2022). narcotic.fda.moph.go.th. https://narcotic.fda.moph.go.th/penalty-narco-phycho-volatile-head/category/narcotic-type1/1
- (n.d.). 26/1/2015 tarihli ve 2015/7238 sayılı Bazı Maddelerin 2313 Sayılı Uyuşturucu Maddelerin Murakabesi Hakkında Kanun Hükümlerine Tabi Tutulması Hakkında Karar. resmigazete.gov.tr. https://www.resmigazete.gov.tr/eskiler/2015/02/20150206-11.htm1
- (n.d.). Misuse of Drugs Act 1971, Schedule 2, Part I: Class A Drugs. UK Government / legislation.gov.uk. https://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I12
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). uscode.house.gov. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section802&num=0&edition=prelim1
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). uscode.house.gov. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section813&num=0&edition=prelim1
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). uscode.house.gov. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section841&num=0&edition=prelim1
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). uscode.house.gov. https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section844&num=0&edition=prelim1
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). federalregister.gov. https://www.federalregister.gov/documents/2023/12/13/2023-27289/schedules-of-controlled-substances-placement-of-25-dimethoxy-4-iodoamphetamine-doi-and1
- (n.d.). Controlled Substance Analogue Enforcement Act of 1986 (21 U.S.C. §§ 802(32), 813). ecfr.gov. https://www.ecfr.gov/current/title-21/section-1308.111
- (n.d.). Alabama Administrative Code r. 420-7-2-.01, Schedule I. admincode.legislature.state.al.us. https://admincode.legislature.state.al.us/administrative-code/420-7-2-A1
- (n.d.). A.R.S. §§ 13-3401(6)(c)(xliii), 13-3407(A)(1). azleg.gov. https://www.azleg.gov/ars/13/03401.htm1
- (n.d.). A.R.S. §§ 13-3401(6)(c)(xliii), 13-3407(A)(1). azleg.gov. https://www.azleg.gov/ars/13/03407.htm1
- (n.d.). Fla. Stat. § 893.03(1)(c)73. leg.state.fl.us. https://www.leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899%2F0893%2FSections%2F0893.03.html1
- (n.d.). Idaho Code § 37-2705(d)(1). legislature.idaho.gov. https://legislature.idaho.gov/statutesrules/idstat/title37/t37ch27/sect37-2705/1
- (n.d.). Iowa Code § 124.204 (Schedule I). legis.iowa.gov. https://www.legis.iowa.gov/docs/code/2025/124.204.pdf1
- (n.d.). Iowa Code § 124.204 (Schedule I). legis.iowa.gov. https://www.legis.iowa.gov/docs/code/2025/124.pdf1
- (n.d.). Minn. Stat. § 152.02, subd. 2(d)(27). revisor.mn.gov. https://www.revisor.mn.gov/statutes/cite/152.021
- (n.d.). Neb. Rev. Stat. § 28-405(c)(30)(xiv). nebraskalegislature.gov. https://nebraskalegislature.gov/laws/statutes.php?statute=28-4051
- (n.d.). Neb. Rev. Stat. § 28-405(c)(30)(xiv). nebraskalegislature.gov. https://nebraskalegislature.gov/FloorDocs/109/PDF/Slip/LB877.pdf1
- (n.d.). 16.19.20.65(E)(89) NMAC. srca.nm.gov. https://www.srca.nm.gov/parts/title16/16.019.0020.html1
- (n.d.). N.C. Gen. Stat. § 90-89(8). ncleg.gov. https://www.ncleg.gov/EnactedLegislation/Statutes/HTML/BySection/Chapter_90/GS_90-89.html1
- (n.d.). Okla. Stat. tit. 63, § 2-204(C)(67). oklegislature.gov. https://www.oklegislature.gov/OK_Statutes/CompleteTitles/os63.pdf1
- (n.d.). S.D. Codified Laws § 34-20B-14. sdlegislature.gov. https://sdlegislature.gov/api/Statutes/34-20B.html?all=true1
- (n.d.). Vermont Regulated Drug Rule § 4.0; 18 V.S.A. §§ 4202, 4205. healthvermont.gov. https://www.healthvermont.gov/sites/default/files/document/reg-regulated-drugs.pdf1
- (n.d.). Vermont Regulated Drug Rule § 4.0; 18 V.S.A. §§ 4202, 4205. legislature.vermont.gov. https://legislature.vermont.gov/statutes/section/18/084/042051
- (n.d.). Va. Code § 54.1-3446(3), Schedule I. law.lis.virginia.gov. https://law.lis.virginia.gov/vacode/title54.1/chapter34/section54.1-3446/1
Further Reading
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the DOC article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.